



Mitochondrial illnesses cause a wide range of mobility problems

Shervin*

Department of Human Genetics, Iran University of Medical Sciences,
Tehran, Iran

Corresponding author: Shervin

E-mail: shervindoc@gmail.com

Genet. Mol. Res. 23 (3): gmr34063

Received: July 28, 2021

Accepted: January 19, 2024

Published: September 26, 2024

Copyright © 2024 Shervin. This is an open-access article distributed under the terms of the Creative Commons Attribution Share A like (CC BY-SA) 4.0 License.

INTRODUCTION

Mitochondrial disease is a term used to describe a range of illnesses caused by mitochondrial malfunction. Mitochondrial diseases are a group of conditions that affect how mitochondria work in your body. Mitochondria make energy in your cells. When mitochondria aren't able to produce enough energy that your body needs, it affects how your organs function.

Mitochondrial diseases can affect almost any part of your body, including the cells of your: Brain, nerves, muscles, kidneys, heart, liver, eyes, ears, pancreas. Mitochondrial diseases are a group of genetic conditions that affect how mitochondria in your cells produce energy. Mitochondria produce most of the energy your body needs. If you have a mitochondrial disease, your cells aren't able to produce enough energy. There isn't a cure, but treatment can prevent life-threatening complications. Mitochondria are energy-generating organelles present in all cells of the human body except red blood cells. They transform food molecules' energy into ATP, which drives most cell processes. Mitochondrial Diseases (MD) are a wide set of mitochondrial dysfunction-related maternally inherited, autosomal dominant, or recessive genetic abnormalities. MD can strike at any age, and many of them appear with a multisystem presentation and a wide range of symptoms. Because mitochondria play such an essential part in neural homeostasis, neurological symptoms such as movement disorders are common. Recent research shows that the dopaminergic nigrostriatal system is particularly susceptible to mitochondrial malfunction, and that mtDNA maintenance abnormalities are commonly linked to nigrostriatal degeneration, which might explain the pathophysiological process. Newer treatment methods that target multiple pathways of mitochondrial failure have been investigated, but clinical studies are still needed to enhance MD patient care.

DESCRIPTION

The job of mitochondria is to process oxygen and convert substances from the foods you eat into energy. Mitochondria exist in nearly every cell in the human body. Mitochondria produce 90% of the energy our bodies need to function. Mitochondrial illnesses are distinct from other diseases in that they are frequently hereditary and mitochondria are so important to cell function. Mitochondrial myopathies are a subgroup of these illnesses with neuromuscular symptoms. Mitochondrial Diseases (MD) are the most prevalent mitochondrial dysfunction-related metabolic illnesses. Mutations in genes encoded by mtDNA or nDNA affect the structure and function of mitochondria in MD; as a result, MD genetics is complicated and evolving. MD is classified genetically into two groups:

- MD produced by mutations in multiple mitochondrial nDNA genes.
- MD caused by primary mtDNA mutations, and MD can develop at any age and has a wide clinical spectrum, however certain clinical syndromes have a characteristic infantile beginning, while others arise

later in life and typically have a milder course.

MD is a diagnosis that is made when a person is diagnosed with the disease. Because of the heterogeneity of the clinical presentation and the existence of symptoms that overlap with other neuromuscular or neurodegenerative diseases, it can be difficult to diagnose. Recurrent clinical symptoms in traditional syndromes linked with particular mtDNA mutations, on the other hand, strongly indicate the diagnosis. Recent research has shown that the nigrostriatal system is particularly vulnerable to mitochondrial dysfunction, and that conditions characterised by a lack of mtDNA maintenance and, as a result, an accumulation of somatic mtDNA damage, are frequently associated with nigrostriatal degeneration, whether or not clinical signs of parkinsonism are present.

CONCLUSION

Movement problems are a component of the MD clinical spectrum in both juvenile and adult patients, and generally occur in conjunction with a mitochondrial multisystem presentation. Dystonia and ataxia are the most prevalent MoDs in children, and they are more commonly linked to mtDNA mutations. Adults with myoclonus, ataxia, and Parkinsonism have been described in mtDNA mutation syndromes or nDNA mutations that cause mtDNA maintenance to be disrupted. The treatment of these diseases is mostly empirical, thus large cohort studies are needed to enhance the management of MD patients with MoD.